Your browser doesn't support javascript.
loading
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.
Li, Ruyuan; Liu, Xingyu; Song, Chunyan; Zhang, Wei; Liu, Jiahao; Jiao, Xiaofei; Yu, Yang; Zeng, Shaoqing; Chi, Jianhua; Zhao, Yingjun; Ma, Guanchen; Huo, Yabing; Li, Ming; Peng, Zikun; Li, Guiling; Jiang, Jie; Gao, Qing-Lei.
Afiliação
  • Li R; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Liu X; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Song C; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zhang W; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Liu J; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Jiao X; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Yu Y; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zeng S; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Chi J; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Zhao Y; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Ma G; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Huo Y; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Li M; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Peng Z; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Li G; Department of Gynecological Oncology, Wuhan Union Hospital, Wuhan, Hubei, China.
  • Jiang J; Department of Obstetrics and Gynecology, Shandong University Qilu Hospital, Jinan, Shandong, China.
  • Gao QL; Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China qingleigao@hotmail.com.
BMJ Open ; 12(5): e058132, 2022 05 24.
Article em En | MEDLINE | ID: mdl-35613822
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Platina / Adenocarcinoma de Células Claras / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Revista: BMJ Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Platina / Adenocarcinoma de Células Claras / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Revista: BMJ Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China